EC
IMCR icon

Elequin Capital’s Immunocore IMCR Stock Holding History

Elequin Capital’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32 Sell
1
-9
-90% -$266 ﹤0.01% 685
2026
Q1 		$302 Sell
10
-27
-73% -$873 ﹤0.01% 591
2025
Q4 		$1.28K Buy
+37
New +$1.31K ﹤0.01% 370
2025
Q1 		– Sell
-73
Closed -$2.15K – 472
2024
Q4 		$2.15K Buy
73
+30
+70% +$948 ﹤0.01% 444
2024
Q3 		$1.34K Buy
+43
New +$1.56K ﹤0.01% 332
2024
Q2 		– Sell
-96
Closed -$6.24K – 264
2024
Q1 		$6.24K Buy
+96
New +$6.59K ﹤0.01% 138

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Elequin Capital's IMCR Position: Q2 2026 in Review

Elequin Capital reduced its Immunocore (IMCR) stake by 90% in Q2 2026, selling an estimated $266 and leaving 1 share worth $32. The position accounts for ﹤0.01% of the portfolio, ranked #685.

Elequin Capital first reported a position in IMCR in Q1 2024 and has held it in 6 quarters since. The position peaked at $6.24K in Q1 2024. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Elequin Capital held 1 share of Immunocore worth $32 as of Q2 2026.
  • Elequin Capital sold 9 Immunocore shares in Q2 2026, an estimated $266.
  • Immunocore made up ﹤0.01% of Elequin Capital's portfolio in Q2 2026, its #685 holding.
  • Elequin Capital first reported a position in Immunocore in Q1 2024 and has held it in 6 quarters since.
  • Elequin Capital's Immunocore position peaked at $6.24K in Q1 2024.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Elequin Capital's 13F filing for Q2 2026, filed 13 Aug 2026.